The stock of Recro Pharma, Inc. (NASDAQ:REPH) hit a new 52-week high and has $11.70 target or 4.00% above today’s $11.25 share price. The 9 months bullish chart indicates low risk for the $215.52M company. The 1-year high was reported on Mar, 14 by Barchart.com. If the $11.70 price target is reached, the company will be worth $8.62 million more. The stock increased 8.38% or $0.87 during the last trading session, reaching $11.25. About 562,900 shares traded or 211.29% up from the average. Recro Pharma, Inc. (NASDAQ:REPH) has risen 26.61% since March 14, 2017 and is uptrending. It has outperformed by 9.91% the S&P500.
SEI Investments Co. is a publicly owned asset management holding company. The company has market cap of $11.93 billion. Through its subsidiaries, the firm provides wealth management, retirement and investment solutions, asset management, asset administration, investment processing outsourcing solutions, financial services, and investment advisory services to its clients. It has a 30.45 P/E ratio. It provides its services to private banks, independent financial advisers, institutional investors, investment managers, investment advisors, wealth management organizations, firms, retirement scheme sponsors, not-for-profit organizations, hedge fund managers, registered investment advisers, independent broker-dealers, financial planners, life insurance agents, defined-benefit schemes, defined-contribution schemes, endowments, foundations, and board-designated fund, through its subsidiaries.
The stock decreased 0.99% or $0.76 during the last trading session, reaching $75.83. About 319,489 shares traded. SEI Investments Co. (SEIC) has risen 1.87% since March 14, 2017 and is uptrending. It has underperformed by 14.83% the S&P500.
Analysts await SEI Investments Co. (NASDAQ:SEIC) to report earnings on April, 18. They expect $0.78 EPS, up 41.82% or $0.23 from last year’s $0.55 per share. SEIC’s profit will be $122.67M for 24.30 P/E if the $0.78 EPS becomes a reality. After $0.58 actual EPS reported by SEI Investments Co. for the previous quarter, Wall Street now forecasts 34.48% EPS growth.
Dudley & Shanley Llc holds 6.01% of its portfolio in SEI Investments Co. for 445,700 shares. Goodnow Investment Group Llc owns 321,405 shares or 4.04% of their US portfolio. Moreover, Hahn Capital Management Llc has 3.71% invested in the company for 614,442 shares. The Maryland-based Df Dent & Co Inc has invested 3.65% in the stock. American Capital Management Inc, a New York-based fund reported 849,780 shares.
Since January 1, 0001, it had 0 insider purchases, and 17 selling transactions for $17.65 million activity.
Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on May, 10. They expect $-0.68 EPS, down 61.90% or $0.26 from last year’s $-0.42 per share. After $-0.63 actual EPS reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 7.94% negative EPS growth.
Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $215.52 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.
Among 9 analysts covering Recro Pharma (NASDAQ:REPH), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma has $21 highest and $1100 lowest target. $16.38’s average target is 45.60% above currents $11.25 stock price. Recro Pharma had 16 analyst reports since August 25, 2015 according to SRatingsIntel. As per Wednesday, September 2, the company rating was initiated by H.C. Wainwright. The firm earned “Buy” rating on Monday, July 31 by Roth Capital. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Tuesday, November 24 by H.C. Wainwright. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Monday, November 14 by Aegis Capital. The firm earned “Buy” rating on Friday, September 16 by TH Capital. As per Thursday, July 20, the company rating was maintained by Roth Capital. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, July 25. The firm has “Buy” rating given on Thursday, November 9 by Roth Capital. The company was initiated on Monday, December 19 by Piper Jaffray. The firm has “Buy” rating by Brean Capital given on Monday, October 3.
Since December 12, 2017, it had 0 buys, and 5 insider sales for $1.43 million activity. SCP Vitalife Partners II LP also sold $41,822 worth of Recro Pharma, Inc. (NASDAQ:REPH) shares. The insider Broadfin Healthcare Master Fund Ltd sold 93,237 shares worth $919,128. 12,964 shares were sold by SCP Vitalife Partners (Israel) II – L.P., worth $115,139 on Tuesday, January 2.